Compounds and methods for treating cancer

Patent metadata

Field	Value
Publication number	US-10934256-B2
Application number	US-201916575733-A
Country	US
Kind code	B2
Filing date	Sep 19, 2019
Priority date	Jun 5, 2015
Publication date	Mar 2, 2021
Grant date	Mar 2, 2021

Abstract

The present application relates to compounds comprising an ester, a thioester, or a hydrazide moiety and methods of synthesizing these compounds. The present application also relates to pharmaceutical compositions containing the compounds and methods of treating cell proliferative disorders mediated by the Hh signaling pathway, such as cancer, by administering the compounds and pharmaceutical compositions to subjects in need thereof.

First claim

The invention claimed is:

1. A compound having formula II:

or a pharmaceutically acceptable salt thereof, wherein:
Z 1 -Z 2 is C(O)—O, O—C(O), C(O)—S, S—C(O), C(O)—NR—NR, or NR—NR—C(O);
Y 1 is N and Y 2 is N or CR 24 ;
each R 24 is independently H, halogen, cyano, unsubstituted or substituted C 1 -C 6 alkyl, or unsubstituted or substituted C 1 -C 6 alkoxy;
n2 is 0, 1, 2, 3, 4, or 5;
each R 21 is independently halogen, cyano, unsubstituted or substituted C 1 -C 6 alkyl, unsubstituted or substituted C 1 -C 6 alkoxy, S(O) o2 -(unsubstituted or substituted C 1 -C 6 alkyl), amino, di-C 1 -C 6 alkylamino, or unsubstituted or substituted C 6 -C 10 aryl;
o2 is 0, 1, or 2;
m2 is 0, 1, 2, 3, or 4;
each R 22 is independently halogen, unsubstituted or substituted C 1 -C 6 alkyl, or unsubstituted or substituted C 1 -C 6 alkoxy;
R 23 is R 25 , S(O) 2 R 25 , C(O)R 25 , OR 25 , or NR 26 R 27 ;
R 25 is unsubstituted or substituted C 3 -C 8 cycloalkyl, unsubstituted or substituted C 6 -C 10 aryl, unsubstituted or substituted heterocyclyl comprising one or two 5- to 8-membered rings and 1-4 heteroatoms selected from O, N, and S, or unsubstituted or substituted heteroaryl comprising one or two 5- to 8-membered rings and 1-4 heteroatoms selected from O, N, and S; and
R 26 and R 27 are each independently H or unsubstituted or substituted C 1 -C 6 alkyl.

2. The compound of claim 1 , having formula IIa:

or a pharmaceutically acceptable salt thereof, wherein:
Z 3 is O, S, or NR—NR;
p2 is 0, 1, 2, 3, or 4; and
each R 28 is independently unsubstituted or substituted C 1 -C 6 alkyl.

3. A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

4. A method of modulating the SMO, comprising contacting the SMO with the compound of claim 1 or a pharmaceutically acceptable salt thereof.

5. A method of treating a disorder mediated by the Hedgehog (Hh) signaling pathway, comprising administering to a subject in need thereof, a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 , wherein Y 2 is CR 24 .

7. The compound of claim 6 , wherein R 24 is H.

8. The compound of claim 1 , wherein n 2 is 1.

9. The compound of claim 1 , wherein R 21 is unsubstituted or substituted straight-chain C 1 -C 6 alkoxy.

10. The compound of claim 9 , wherein R 21 is trifluoromethoxy.

11. The compound of claim 1 , wherein m 2 is 1.

12. The compound of claim 1 , wherein R 22 is unsubstituted or substituted straight-chain C 1 -C 6 alkyl.

13. The compound of claim 12 , wherein R 22 is methyl.

14. The compound of claim 1 , wherein R 23 is heterocyclyl optionally substituted with one or more substituents independently selected from halogen, OH, cyano, nitro, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, and amino.

15. The compound of claim 14 , wherein R 23 is morpholinyl substituted with two substituents independently selected from methyl, ethyl, and propyl.

16. The compound of claim 1 , which is:

or a pharmaceutically acceptable salt thereof, wherein Z is O, S, or NH—NH.

17. The compound of claim 16 , which is:

or a pharmaceutically acceptable salt thereof, wherein Z is O.

18. The compound of claim 1 , which is:

or a pharmaceutically acceptable salt thereof, wherein Z is O, S, or NH—NH.

Assignees

• Dana Farber Cancer Inst Inc

Inventors

• Bradner James
• Erb Michael
• Qi Jun

Classifications

• C07D401/14

  containing three or more hetero rings · CPC title

• C07D211/58

  attached in position 4 · CPC title

• C07D211/44 Primary

  attached in position 4 · CPC title

• C07D401/04

  directly linked by a ring-member-to-ring-member bond · CPC title

• C07D239/78

  with hetero atoms directly attached in position 2 · CPC title